Peptide–drug
conjugates that self-assemble into supramolecular
nanomaterials have promise for uses in drug delivery. These discrete
molecular species offer high and precise drug loading, affording efficient
carriers for various therapeutic agents. Their peptide modules, meanwhile,
enable biological targeting and stimuli-responsive function while
also ordering the assembled nanostructure. The often hydrophobic drug
payload likewise acts as a directive for self-assembly in aqueous
media. Though accessible synthetic methods have allowed for extensive
exploration of the peptide design space, the specific contributions
of the drug molecule and its linker to the resulting assembly have
been less explored. Hydrophobic drugs frequently have planar domains,
conjugated π-systems, and isolated polar groups, which in turn
can lead to specific and directional self-interactions. These energies
of interaction affect the free energy landscape of self-assembly and
may impact the form and assembly process of the desired nanomaterial.
Here, two model supramolecular peptide–drug conjugates (sPDCs)
are explored, composed of the corticosteroid dexamethasone conjugated
to a conserved peptide sequence via two different linker chemistries.
The choice of linker, which alters the orientation, rotational freedom,
and number of stereoisomers of the prodrug in the final sPDC, impacts
the mechanism and energetic barrier of assembly as well as the nano/macroscale
properties of the resultant supramolecular materials. Accordingly,
this work demonstrates the nonzero energetic contributions of the
drug and its linker to sPDC self-assembly, provides a quantitative
exploration of the sPDC free energy landscape, and suggests design
principles for the enhanced control of sPDC nanomaterials to inform
future applications as therapeutic drug carriers.